**Supplemental Table 2.** Time-updated Cox proportional hazards results and 95% confidence intervals by outcome.

|  |  |  |  |
| --- | --- | --- | --- |
| **Factor** | **Hazard Ratio** | **95% CI** | **P Value** |
| *Confirmed Virologic Failure*a |
| Tenofovir group | 1.470 | 1.235, 1.750 | <0.001 |
| Female gender | 0.782 | 0.628, 0.974 | 0.028 |
| HBV co-infection | 0.954 | 0.765, 1.191 | 0.680 |
| HCV co-infection | 1.064 | 0.773, 1.464 | 0.703 |
| TB co-infection | 1.962 | 1.317, 2.923 | 0.001 |
| Age (years) | 0.982 | 0.971, 0.993 | 0.001 |
| CD4 (log10)e | 0.460 | 0.377, 0.560 | <0.001 |
| HIV RNA (log10)e | 1.156 | 1.045, 1.278 | 0.005 |
| Creatinine (μmol/L)e | 0.998 | 0.995, 0.999 | 0.049 |
| Hemoglobin (g/L)e | 0.993 | 0.988, 0.998 | 0.003 |
| *Unconfirmed Virologic Failure* b |
| Tenofovir group | 0.847 | 0.640, 1.122 | 0.249 |
| Female gender | 0.522 | 0.385, 0.709 | <0.001 |
| HBV co-infection | 1.576 | 1.152, 2.157 | 0.004 |
| HCV co-infection | 1.000 | 0.580, 1.725 | 1.000 |
| TB co-infection | 0.991 | 0.487, 2.018 | 0.980 |
| Age (years) | 0.976 | 0.959, 0.994 | 0.010 |
| CD4 (log10)e | 0.999 | 0.999, 1.001 | 0.861 |
| HIV RNA (log10)e | 2.550 | 2.308, 2.818 | <0.001 |
| ALT (µkat/L)e | 0.806 | 0.613, 1.060 | 0.122 |
| Creatinine (μmol/L)e | 0.997 | 0.993, 1.001 | 0.182 |
| Hemoglobin (g/L)e | 0.986 | 0.979, 0.993 | <0.001 |
| *Regimen Switch* c |
| Tenofovir group | 1.341 | 1.147, 1.567 | <0.001 |
| Female gender | 0.646 | 0.552, 0.755 | <0.001 |
| HBV co-infection | 0.715 | 0.535, 0.955 | 0.023 |
| HCV co-infection | 0.456 | 0.257, 0.809 | 0.007 |
| TB co-infection | 9.056 | 7.546, 10.867 | <0.001 |
| Age (years) | 1.007 | 0.999, 1.015 | 0.061 |
| CD4 (log10)e | 0.998 | 0.997, 0.998 | <0.001 |
| HIV RNA (log10)e | 1.192 | 1.126, 1.262 | <0.001 |
| ALT (µkat/L)e | 1.025 | 0.932, 1.128 | 0.607 |
| Creatinine (μmol/L)e | 1.001 | 0.999, 1.002 | 0.053 |
| Hemoglobin (g/L)e | 0.979 | 0.975, 0.983 | <0.001 |
| Regimen x HBV | 4.050 | 2.892, 5.670 | <0.001 |
| Regimen x HCV | 2.256 | 1.184, 4.300 | 0.013 |
| *Discontinuation* d |
| Tenofovir group | 1.090 | 0.928, 1.282 | 0.293 |
| Female gender | 1.194 | 0.955, 1.494 | 0.120 |
| HBV co-infection | 1.177 | 0.974, 1.422 | 0.092 |
| HCV co-infection | 1.500 | 1.179, 1.908 | 0.001 |
| TB co-infection | 1.332 | 0.899, 1.975 | 0.154 |
| Age (years) | 0.996 | 0.986, 1.006 | 0.401 |
| CD4 (log10)e | 1.000 | 0.999, 1.001 | 0.419 |
| HIV RNA (log10)e | 1.181 | 1.093, 1.277 | <0.001 |
| ALT (µkat/L)e | 1.056 | 0.985, 1.134 | 0.125 |
| Creatinine e | 0.999 | 0.996, 1.002 | 0.473 |
| Hemoglobin (g/L)e | 0.992 | 0.988, 0.997 | 0.002 |

Abbreviations: CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; WHO, World Health Organization; TB, tuberculosis.

a 6225 cases, 79390 observations.

b 6160 cases, 73639 observations.

c 6198 cases, 71982 observations.

d 6230 cases, 80710 observations.

e Time-updated covariates.